Related Experiment Videos
Hepatocellular carcinoma: systemic treatments
Massimo Di Maio1, Ermelinda De Maio, Francesco Perrone
1Medical Oncology, National Cancer Institute, Naples, Italy. bdaniele@sirio-oncology.it
Journal of Clinical Gastroenterology
|October 24, 2002
Summary
Chemotherapy and hormone therapy offer no clear survival advantage for hepatocellular carcinoma (HCC). Interferon shows promise in specific settings, but new targeted therapies are needed for advanced liver cancer.
Area of Science:
- Hepatology
- Oncology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent malignancy globally, with rising rates in Western nations.
- Current pharmacologic treatments for HCC include chemotherapy, hormone therapy, and immunotherapy.
Purpose of the Study:
- To review the efficacy of existing pharmacologic treatments for HCC.
- To identify promising future therapeutic strategies for liver cancer.
Main Methods:
- Review of randomized controlled trials and clinical studies on HCC pharmacotherapies.
- Analysis of treatment outcomes, including overall survival and tolerability.
Main Results:
- Chemotherapy (single or combination) lacks reproducible survival benefits in HCC.
- Hormone therapies like tamoxifen and antiandrogens have not improved survival.
- Octreotide shows potential in preliminary studies; further research is required.
- Interferon may be beneficial in adjuvant or preventive settings for cirrhotic patients, but not for advanced HCC due to poor tolerability.
Conclusions:
- Current chemotherapy and hormone therapies are not standard strategies for HCC.
- Interferon warrants further investigation for specific HCC patient groups.
- Novel therapies, including targeted drugs, cyclooxygenase inhibitors, and gene therapy, represent future directions for HCC treatment.